These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31837422)

  • 1. Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.
    Henderson MX; Covell DJ; Chung CH; Pitkin RM; Sandler RM; Decker SC; Riddle DM; Zhang B; Gathagan RJ; James MJ; Trojanowski JQ; Brunden KR; Lee VMY; Luk KC
    Neurobiol Dis; 2020 Mar; 136():104712. PubMed ID: 31837422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.
    Tran HT; Chung CH; Iba M; Zhang B; Trojanowski JQ; Luk KC; Lee VM
    Cell Rep; 2014 Jun; 7(6):2054-65. PubMed ID: 24931606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological biochemistry of alpha-synucleinopathy.
    Iwatsubo T
    Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.
    Fagerqvist T; Lindström V; Nordström E; Lord A; Tucker SM; Su X; Sahlin C; Kasrayan A; Andersson J; Welander H; Näsström T; Holmquist M; Schell H; Kahle PJ; Kalimo H; Möller C; Gellerfors P; Lannfelt L; Bergström J; Ingelsson M
    J Neurochem; 2013 Jul; 126(1):131-44. PubMed ID: 23363402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.
    Bae EJ; Lee HJ; Rockenstein E; Ho DH; Park EB; Yang NY; Desplats P; Masliah E; Lee SJ
    J Neurosci; 2012 Sep; 32(39):13454-69. PubMed ID: 23015436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
    Iwatsubo T
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies.
    Tagliafierro L; Glenn OC; Zamora ME; Beach TG; Woltjer RL; Lutz MW; Chiba-Falek O
    Alzheimers Dement; 2017 Nov; 13(11):1237-1250. PubMed ID: 28431219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
    Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
    Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential insular cortex subregional vulnerability to α-synuclein pathology in Parkinson's disease and dementia with Lewy bodies.
    Fathy YY; Jonker AJ; Oudejans E; de Jong FJJ; van Dam AW; Rozemuller AJM; van de Berg WDJ
    Neuropathol Appl Neurobiol; 2019 Apr; 45(3):262-277. PubMed ID: 29797340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Therapeutic Strategies for Lewy Body Dementias.
    Velayudhan L; Ffytche D; Ballard C; Aarsland D
    Curr Neurol Neurosci Rep; 2017 Sep; 17(9):68. PubMed ID: 28741230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.
    Masliah E; Rockenstein E; Mante M; Crews L; Spencer B; Adame A; Patrick C; Trejo M; Ubhi K; Rohn TT; Mueller-Steiner S; Seubert P; Barbour R; McConlogue L; Buttini M; Games D; Schenk D
    PLoS One; 2011 Apr; 6(4):e19338. PubMed ID: 21559417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Valera E; Masliah E
    Mov Disord; 2016 Feb; 31(2):225-34. PubMed ID: 26388203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.
    Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E
    J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.